Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers

This study is not yet open for participant recruitment.
Verified May 2012 by Dipexium Pharmaceuticals, LLC
Sponsor:
Information provided by (Responsible Party):
Dipexium Pharmaceuticals, LLC
ClinicalTrials.gov Identifier:
NCT01594762
First received: May 7, 2012
Last updated: May 10, 2012
Last verified: May 2012

May 7, 2012
May 10, 2012
October 2012
February 2013   (final data collection date for primary outcome measure)
Clinical Response [ Time Frame: 28 days ] [ Designated as safety issue: No ]
Clinical Response will be classified according to the Investigator's medical judgment as one of the following: infection resolved, infection not resolved, recurrent infection, or unevaluable.
Same as current
Complete list of historical versions of study NCT01594762 on ClinicalTrials.gov Archive Site
  • Microbiological Response [ Time Frame: 28 days ] [ Designated as safety issue: No ]
    Microbiological Response to therapy will be categorized as one of the following: complete microbiological response, partial microbiological response, no microbiological response, colonization, superinfection, relapse, reinfection, unevaluable or not applicable.
  • Incidence and severity of adverse events [ Time Frame: 28 days ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Acetate Cream 1% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers

The purpose of this study is to establish the clinical superiority and the safety of topical pexiganan acetate cream 1% plus standard local wound care as compared to placebo cream plus standard local wound care, in the treatment of mildly infected diabetic foot ulcers.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Diabetic Foot Infection
  • Drug: Pexiganan acetate cream 1%
    14 days of treatment
    Other Name: MSI-78
  • Drug: Placebo cream
    14 days of treatment
  • Other: Standard wound care
    14 days of treatment
  • Placebo Comparator: Placebo control
    Drug: placebo cream
    Interventions:
    • Drug: Placebo cream
    • Other: Standard wound care
  • Experimental: Pexiganan acetate cream 1%
    Drug: pexiganan acetate cream 1%
    Interventions:
    • Drug: Pexiganan acetate cream 1%
    • Other: Standard wound care
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
180
February 2013
February 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Diabetes mellitus.
  2. Male or female at least 18 years old.
  3. Subject must agree to adhere to all protocol procedures and return for all scheduled visits, and must be willing and able to provide written informed consent.
  4. Subject is to be treated on an outpatient basis.
  5. Full thickness ulcer or a partial thickness ulcer on the foot distal to the malleoli with a surface area ≥ 1 cm2 after the wound has undergone appropriate debridement.
  6. Localized mild infection of the ulcer.
  7. The diagnosis of mild infection must be confirmed immediately following debridement at Baseline.
  8. Subject must have plain radiographs taken within 2 days prior to entry showing no evidence of bony abnormalities consistent with osteomyelitis, or gas compatible with tissue crepitus, in the affected foot.

Exclusion Criteria:

  1. IDSA-defined moderate infection, including cellulitis extending > 2 cm; lymphangitis; spread beneath the fascia; deep tissue abscess; gangrene; muscle, joint, or bone involvement.
  2. IDSA-defined severe infection, including systemic toxicity or metabolic instability.
  3. Infected diabetic foot ulcer that is associated with local wound complications such as prosthetic materials or protruding surgical hardware.
  4. > 1 infected foot ulcer.
  5. Subject is currently receiving topical antimicrobial treatment for a localized infection of the study ulcer and whose infection is improving in response to treatment.
  6. Subject has received a systemic antibiotic within 48 hours prior to Screening.
  7. Concurrent systemic antimicrobials during the study period for any infection, including diabetic foot ulcer.
  8. Bone or joint involvement is suspected based on clinical examination or plain X-ray.
  9. Clinically significant peripheral arterial disease requiring vascular intervention.
  10. Subject is expected to be unable to care for the ulcer or return for all scheduled visits because of hospitalization, vacation, disability, etc. during the study period, or is unable to safely monitor the infection status at home.
Both
18 Years and older
No
Contact: Micahel H. Silverman, MD 781-631-8596 msilverman@biostrategics.com
Not Provided
 
NCT01594762
DPX-306
Yes
Dipexium Pharmaceuticals, LLC
Dipexium Pharmaceuticals, LLC
Not Provided
Study Director: Michael H. Silverman, MD Biostrategics Consulting Ltd
Dipexium Pharmaceuticals, LLC
May 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP